TOFA may drive weight loss without reducing food intake
The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.
By
Andrea Surnit
August 27, 2026
Clinical Scorecard: TOFA may drive weight loss without reducing food intake
At a Glance
Category Detail
Condition Obesity and related metabolic diseases Key Mechanisms Inhibition of acetyl-CoA carboxylases 1 and 2; partial activation of PPAR alpha and delta Target Population Male mice with diet-induced obesity Care Setting Preclinical research
Key Highlights
TOFA reduced body weight by an average of 18% without affecting food intake. Improved fasting blood glucose, insulin levels, and glucose tolerance. Increased energy expenditure without increased physical activity. Reduced liver triglycerides and cholesterol levels. Combination therapy with TOFA and incretin analogs showed greater weight loss. Guideline-Based Recommendations
Diagnosis
Assessment of obesity and metabolic dysfunction in animal models. Management
TOFA treatment for weight loss and metabolic improvement. Monitoring & Follow-up
Regular evaluation of body weight, glucose levels, and lipid profiles. Risks
Incomplete characterization of safety profile and potential subclinical toxicity. Patient & Prescribing Data
Male mice; further studies needed for female models.
TOFA shows potential for weight loss without reducing food intake.
Clinical Best Practices
Consider combination therapy for enhanced weight loss and metabolic control. Monitor metabolic parameters during TOFA treatment. Related Resources & Content
